Craft

Humacyte

Stock Price

$5.3

2024-10-29

Market Capitalization

$666.7 M

2024-10-29

Revenue

$2 M

FY, 2025

Humacyte Summary

Company Summary

Overview
Humacyte is a regenerative medical technology company focused on the development of human acellular matrix products for vascular and non-vascular applications. It uses its proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues.
Type
Public
Status
Active
Founded
2004
HQ
Durham, NC, US | view all locations
Website
https://humacyte.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Douglas L. Blankenship

    Douglas L. Blankenship, Chief Financial Officer

    • Laura E. Niklason

      Laura E. Niklason, Founder, President & Chief Executive Officer, Director

      • Jeffrey H

        Jeffrey H, Chief Surgical Officer

        • Heather Prichard

          Heather Prichard, Chief Operating Officer

          LocationsView all

          1 location detected

          • Durham, NC HQ

            United States

          Humacyte Financials

          Summary Financials

          Revenue (Q1, 2026)
          $495.0K
          Gross profit (Q1, 2026)
          ($1.5M)
          Net income (Q1, 2026)
          ($17.6M)
          Cash (Q1, 2026)
          $48.5M
          Enterprise value
          $681.7M

          Footer menu